Tauber Eye Center Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2014
NCT02163824
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Tauber Eye Center

Active Ingredients

Drugs in Phase 4 Trials (1)

lifitegrast (xiidra) (2 trials)

Drugs in Phase 3 Trials (1)

loteprednol (lotemax) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharitis (Phase 2)

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Eye Infections (Phase 3)

Inflammation (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 2